Breast Cancer News and Research

Latest Breast Cancer News and Research

GenSpera issued additional patent for G-202

GenSpera, Inc. announced that its patent application, entitled "Tissue Specific Prodrugs," has been issued by the United States Patent and Trademark Office as US Patent 7,767,648. The patent covers the method of use for G-202, GenSpera's lead oncology drug, which is currently in a Phase I clinical study treating cancer patients whose disease has progressed after other treatments.

11 Aug 2010

Premier international conference to highlight understanding of cancer disparities

This year, the American Association for Cancer Research will host its third conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved at the Loews Miami Beach Hotel in Miami, Fla.

11 Aug 2010

Study finds hormone replacement therapy increases breast cancer risk

A new analysis of the California Teachers Study, which analyzed hormone replacement therapy use among 2,857 women for almost 10 years, underscores the need for personalized risk-benefit discussions before women begin hormone therapy."This is evidence that the story is complicated," said Tanmai Saxena, an M.D./Ph.D. student at the Keck School of Medicine at the University of Southern California. "The benefits of hormone therapy for relief of postmenopausal symptoms among women are clear, but the risks are more complicated than we had previously thought."

11 Aug 2010

Study shows physicians reluctant to use finasteride for prostate cancer

Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

11 Aug 2010

Clarient receives patent for Mammostrat breast cancer prognostic test

Clarient, Inc. a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United States Patent and Trademark Office and the European Patent Office have allowed patents covering the technology behind Clarient Insight Dx Mammostrat, a test designed to aid in the classification of the risk of recurrence of breast cancer following surgery and initial treatment.

11 Aug 2010

Smile Pink campaign encourages women, men to support early breast cancer testing

Over five hundred dentists from around the United States have joined forces in an exciting new initiative aimed at promoting early detection in breast cancer. Dubbed "Smile Pink", the campaign encourages women and men to show their support of early breast cancer testing by adding a stylish Pink Swarovski Crystal to their smile.

11 Aug 2010

Progestins have tumor-stage specific effects that determine promotion, suppression: Study

Progestins are used in hormone replacement therapies to counteract the negative effects of estrogen on the uterus and reduce the risk of uterine cancer. However, evidence in recent studies and clinical trials has demonstrated that progestins increase the risk of breast cancer. Now, University of Missouri researchers have compared four types of progestins used in hormone replacement therapies and found significantly different outcomes on the progression of breast cancer in an animal model depending on the type of progestins used.

11 Aug 2010

Scientists develop new method to enable drug release inside cancer cells

Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field.The new system - the first to utilize a class of porous nanomaterials driven by a magnetic core - has the potential to improve both targeted drug-delivery and magnetic resonance imaging in the treatment of cancer and other diseases.

11 Aug 2010

Breath test to detect cancer: Study

According to researchers cancer may soon be detectable using a breath test. They are now developing sensors that can detect chemical markers of lung, breast, bowel and prostate cancer in a person's breath. The new portable device has been purported as an “electronic nose” that can detect early cancers. As a cancer grows, the surface of the cells emits chemicals. The research found that sensors – involving gold nanoparticles – could be used to detect these chemicals in the breath.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Research on role of ADAM12 gene in breast cancer

A microscopic gene may play a gigantic role when it comes to cancerous tissue in the human body, according to one Kansas State University research team.The team is investigating mutation within the ADAM12 gene of the A Disintegrin and Metalloprotease family, or ADAM family, and its role in breast cancer."We want to know whether ADAM12 is a good guy or a bad guy in breast cancer," said Anna Zolkiewska, associate professor of biochemistry and research team leader.

10 Aug 2010

Scientist to research on molecular machinery of breast cancer

Someone in the world is diagnosed with breast cancer every 23 seconds. It is the leading cause of cancer death worldwide among women and approximately 456,000 die from the disease each year. At The University of Texas Health Science Center at Houston (UTHealth), a scientist is taking aim at the molecular machinery behind this disease.

10 Aug 2010

Study to evaluate sensitivity of mammography combined with somo•v ABUS technology in breast cancer screening

Henry Ford West Bloomfield Hospital announced today that it has joined U-Systems national clinical research study designed to evaluate whether digital mammography, when combined with the somo•v Automated Breast Ultrasound System (ABUS) from U-Systems, Inc (Sunnyvale, CA), is more sensitive in detecting breast lesions compared to mammography alone in women with dense breasts. Henry Ford West Bloomfield Hospital is the only site in Michigan, and one of only ten breast cancer centers in the entire country, currently recruiting women for the SOMO•INSIGHT clinical study.

10 Aug 2010

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

GTx second-quarter net loss increases to $12.9 million

GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the Phase III clinical trial of toremifene 20 mg.

9 Aug 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Cancer is a leading cause of mortality worldwide, accounting for more than one in ten deaths. By 2030, the global burden is expected to exceed 12 million.

9 Aug 2010

Oil Can Henry's customers raise $45,401 to support Susan G. Komen for the Cure

Oil Can Henry's customers rose to the challenge in July and helped the company raise $45,401 to support the Oregon and SW Washington Affiliate of Susan G. Komen for the Cure to help save lives and end breast cancer. Over the week-long fundraising effort, Oil Can Henry's locations in Oregon and Southwest Washington performed oil changes on 15,746 vehicles. In addition, customers had the opportunity to donate directly to Komen at the time of service.

7 Aug 2010

BCF publishes two new patient publications

The Bone and Cancer Foundation is announcing the publishing of two new patient publications on Pain Management and Physical Therapy and other Rehabilitation Therapies. Other publication topics include: Breast Cancer, Prostate Cancer, Lung Cancer, Osteonecrosis of the Jaw, Vitamin D, Surgery, Myeloma and Osteosarcoma.

7 Aug 2010

Breast Cancer News and Research

Latest Breast Cancer News and Research

GenSpera issued additional patent for G-202

Premier international conference to highlight understanding of cancer disparities

Study finds hormone replacement therapy increases breast cancer risk

Study shows physicians reluctant to use finasteride for prostate cancer

Clarient receives patent for Mammostrat breast cancer prognostic test

Smile Pink campaign encourages women, men to support early breast cancer testing

Progestins have tumor-stage specific effects that determine promotion, suppression: Study

Scientists develop new method to enable drug release inside cancer cells

Breath test to detect cancer: Study

Synta second-quarter net loss increases to $9.1 million

Research on role of ADAM12 gene in breast cancer

Scientist to research on molecular machinery of breast cancer

Study to evaluate sensitivity of mammography combined with somo•v ABUS technology in breast cancer screening

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

GTx second-quarter net loss increases to $12.9 million

ESMO Congress provides forum for presentation of new research on treatment of cancer

Oil Can Henry's customers raise $45,401 to support Susan G. Komen for the Cure

BCF publishes two new patient publications

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Breast Cancer News and Research

Latest Breast Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in